ACAD vs. COO

Last updated Jun 4, 2026

ACAD (ACADIA Pharmaceuticals Inc.) and COO (The Cooper Companies, Inc.) are both stocks. Both are in the Healthcare sector — ACAD in Biotechnology, COO in Medical Instruments & Supplies. Over the past 10 years, ACAD returned -5.07%/yr vs 3.87%/yr for COO. At a 0.25 correlation, their price movements are largely independent.

Performance

ACAD vs. COO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ACADIA Pharmaceuticals Inc. (ACAD) and The Cooper Companies, Inc. (COO). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ACAD achieves a -19.77% return, which is significantly higher than COO's -26.38% return. Over the past 10 years, ACAD has underperformed COO with an annualized return of -5.07%, while COO has yielded a comparatively higher 3.87% annualized return.

ACAD

• 1D: 2.58%
• 1M: -3.42%
• YTD: -19.77%
• 6M: -17.19%
• 1Y: -2.50%
• 3Y*: -4.51%
• 5Y*: -1.99%
• 10Y*: -5.07%

COO

• 1D: 1.43%
• 1M: -1.92%
• YTD: -26.38%
• 6M: -20.58%
• 1Y: -9.82%
• 3Y*: -12.19%
• 5Y*: -8.76%
• 10Y*: 3.87%

*Multi-year figures are annualized to reflect compound growth (CAGR)

ACAD vs. COO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ACAD ACADIA Pharmaceuticals Inc.	-19.77%	45.56%	-41.39%	96.67%	-31.79%	-56.34%	24.96%	164.56%	-46.30%	4.40%
COO The Cooper Companies, Inc.	-26.38%	-10.85%	-2.83%	14.47%	-21.06%	15.33%	13.10%	26.27%	16.84%	24.59%

Correlation

The correlation between ACAD and COO is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.28
Correlation (3Y) Calculated over the trailing 3-year period	0.28
Correlation (5Y) Calculated over the trailing 5-year period	0.30
Correlation (10Y) Calculated over the trailing 10-year period	0.28
Correlation (All Time) Calculated using the full available price history since May 28, 2004	0.25

Fundamentals

Market Cap ACAD : $3.70B COO : $11.87B
EPS ACAD : $2.20 COO : $2.02
PE Ratio ACAD : 9.75 COO : 29.83
PS Ratio ACAD : 3.34 COO : 2.88
PB Ratio ACAD : 2.97 COO : 1.42
Total Revenue (TTM) ACAD : $1.10B COO : $4.15B
Gross Profit (TTM) ACAD : $758.58M COO : $2.67B
EBITDA (TTM) ACAD : $104.56M COO : $962.00M

Return for Risk

ACAD vs. COO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ACAD

ACAD Risk / Return Rank: 36
ACAD Sharpe Ratio Rank: 38
ACAD Sortino Ratio Rank: 33
ACAD Omega Ratio Rank: 33
ACAD Calmar Ratio Rank: 38
ACAD Martin Ratio Rank: 37

COO

COO Risk / Return Rank: 26
COO Sharpe Ratio Rank: 26
COO Sortino Ratio Rank: 24
COO Omega Ratio Rank: 24
COO Calmar Ratio Rank: 30
COO Martin Ratio Rank: 26

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ACAD vs. COO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ACADIA Pharmaceuticals Inc. (ACAD) and The Cooper Companies, Inc. (COO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ACAD	COO	Difference
Sharpe ratio Return per unit of total volatility	-0.07	-0.33	+0.27
Sortino ratio Return per unit of downside risk	0.17	-0.28	+0.44
Omega ratio Gain probability vs. loss probability	1.02	0.97	+0.05
Calmar ratio Return relative to maximum drawdown	-0.09	-0.33	+0.24
Martin ratio Return relative to average drawdown	-0.17	-0.81	+0.64
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ACAD vs. COO - Sharpe Ratio Comparison

The current ACAD Sharpe Ratio is -0.07, which is higher than the COO Sharpe Ratio of -0.33. The chart below compares the historical Sharpe Ratios of ACAD and COO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	ACAD	COO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.07	-0.33	+0.27
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.04	-0.31	+0.27
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.08	0.14	-0.22
Sharpe Ratio (All Time) Calculated using the full available price history	0.06	0.11	-0.04

Drawdowns

ACAD vs. COO - Drawdown Comparison

The maximum ACAD drawdown since its inception was -96.29%, roughly equal to the maximum COO drawdown of -98.88%. Use the drawdown chart below to compare losses from any high point for ACAD and COO.

Drawdown Indicators

	ACAD	COO	Difference
Max Drawdown Largest peak-to-trough decline	-96.29%	-98.88%	+2.59%
Max Drawdown (1Y) Largest decline over 1 year	-27.58%	-30.05%	+2.47%
Max Drawdown (3Y) Largest decline over 3 years	-57.87%	-46.97%	-10.90%
Max Drawdown (5Y) Largest decline over 5 years	-57.87%	-48.24%	-9.63%
Max Drawdown (10Y) Largest decline over 10 years	-77.18%	-48.24%	-28.94%
Current Drawdown Current decline from peak	-62.40%	-47.04%	-15.36%
Average Drawdown Average peak-to-trough decline	-50.15%	-40.56%	-9.59%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.70%	12.19%	+2.51%

Volatility

ACAD vs. COO - Volatility Comparison

ACADIA Pharmaceuticals Inc. (ACAD) has a higher volatility of 10.49% compared to The Cooper Companies, Inc. (COO) at 5.97%. This indicates that ACAD's price experiences larger fluctuations and is considered to be riskier than COO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ACAD	COO	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.49%	5.97%	+4.52%
Volatility (6M) Calculated over the trailing 6-month period	26.13%	17.40%	+8.73%
Volatility (1Y) Calculated over the trailing 1-year period	36.89%	29.43%	+7.46%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	55.51%	28.84%	+26.67%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	62.09%	27.69%	+34.40%

Dividends

ACAD vs. COO - Dividend Comparison

Neither ACAD nor COO has paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ACAD ACADIA Pharmaceuticals Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
COO The Cooper Companies, Inc.	0.00%	0.00%	0.00%	0.02%	0.02%	0.01%	0.02%	0.02%	0.02%	0.03%	0.03%	0.04%

Financials

ACAD vs. COO - Profitability Comparison

The chart below illustrates the profitability comparison between ACADIA Pharmaceuticals Inc. and The Cooper Companies, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ACAD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ACADIA Pharmaceuticals Inc. reported a gross profit of 0.00 and revenue of 268.06M. Therefore, the gross margin over that period was 0.0%.

COO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, The Cooper Companies, Inc. reported a gross profit of 695.20M and revenue of 1.02B. Therefore, the gross margin over that period was 67.9%.

ACAD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ACADIA Pharmaceuticals Inc. reported an operating income of -4.62M and revenue of 268.06M, resulting in an operating margin of -1.7%.

COO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, The Cooper Companies, Inc. reported an operating income of 212.80M and revenue of 1.02B, resulting in an operating margin of 20.8%.

ACAD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ACADIA Pharmaceuticals Inc. reported a net income of 3.64M and revenue of 268.06M, resulting in a net margin of 1.4%.

COO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, The Cooper Companies, Inc. reported a net income of 130.80M and revenue of 1.02B, resulting in a net margin of 12.8%.

Frequently Asked Questions

Can I hold both ACAD and COO in my portfolio?

ACAD and COO have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ACAD or COO?

ACAD has higher volatility (10.49%) compared to COO (5.97%). In terms of maximum drawdown, ACAD dropped -96.29% vs COO's -98.88%.

Which has better risk-adjusted returns?

ACAD currently has the higher Sharpe Ratio (-0.07 vs -0.33), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.